Robert Driscoll
Stock Analyst at Wedbush
(4.59)
# 294
Out of 4,412 analysts
116
Total ratings
48.48%
Success rate
42.15%
Average return
Main Sectors:
Top Industries:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACET Adicet Bio | Reiterates: Outperform | $5 | $1.68 | +197.62% | 7 | Apr 23, 2024 | |
| ALPN Alpine Immune Sciences | Downgrades: Neutral | n/a | $64.56 | - | 7 | Apr 11, 2024 | |
| GERN Geron | Reiterates: Outperform | $6 | $3.79 | +58.31% | 7 | Apr 10, 2024 | |
| FHTX Foghorn Therapeutics | Reiterates: Outperform | $13 | $5.49 | +136.79% | 6 | Apr 10, 2024 | |
| BDTX Black Diamond Therapeutics | Maintains: Outperform | $10 → $16 | $5.89 | +171.65% | 7 | Apr 8, 2024 | |
| APRE Aprea Therapeutics | Maintains: Outperform | $9 → $11 | $5.20 | +111.54% | 2 | Mar 27, 2024 | |
| CMPX Compass Therapeutics | Reiterates: Outperform | $8 | $1.45 | +451.72% | 2 | Mar 22, 2024 | |
| TYRA Tyra Biosciences | Reiterates: Outperform | $28 | $15.67 | +78.69% | 4 | Mar 21, 2024 | |
| CTMX CytomX Therapeutics | Reiterates: Neutral | $3 | $1.59 | +88.68% | 7 | Mar 12, 2024 | |
| IGMS IGM Biosciences | Reiterates: Outperform | $20 | $9.40 | +112.77% | 6 | Mar 8, 2024 | |
| ELEV Elevation Oncology | Maintains: Outperform | $5 → $8 | $3.62 | +120.99% | 6 | Mar 7, 2024 | |
| KURA Kura Oncology | Reiterates: Outperform | $37 | $19.65 | +88.30% | 4 | Feb 28, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Neutral | $12 → $15 | $11.06 | +35.62% | 8 | Feb 28, 2024 | |
| ARVN Arvinas | Maintains: Outperform | $33 → $59 | $32.37 | +82.27% | 4 | Feb 28, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Outperform | $30 | $15.55 | +92.93% | 4 | Feb 22, 2024 | |
| CGEM Cullinan Oncology | Initiates: Outperform | $30 | $25.30 | +18.58% | 1 | Feb 15, 2024 | |
| GLUE Monte Rosa Therapeutics | Initiates: Outperform | $11 | $5.33 | +106.38% | 1 | Feb 15, 2024 | |
| OMGA Omega Therapeutics | Reiterates: Outperform | $12 | $2.27 | +428.63% | 3 | Jan 4, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $43 | $39.94 | +7.66% | 5 | Nov 13, 2023 | |
| REPL Replimune Group | Reiterates: Outperform | $52 | $6.42 | +709.97% | 4 | Nov 8, 2023 | |
| JANX Janux Therapeutics | Reiterates: Outperform | $24 | $47.39 | -49.36% | 5 | Nov 8, 2023 | |
| DAWN Day One Biopharmaceuticals | Maintains: Outperform | $39 → $35 | $14.92 | +134.58% | 5 | Nov 7, 2023 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $9 | $6.75 | +33.33% | 1 | Aug 24, 2023 | |
| BCEL Atreca | Downgrades: Neutral | $4 → $1 | $0.08 | +1,112.12% | 4 | Aug 14, 2023 | |
| TNGX Tango Therapeutics | Reiterates: Outperform | $18 | $7.44 | +141.94% | 2 | May 10, 2023 | |
| ABUS Arbutus Biopharma | Upgrades: Outperform | n/a | $2.73 | - | 4 | May 19, 2020 |
Adicet Bio
Apr 23, 2024
Reiterates: Outperform
Price Target: $5
Current: $1.68
Upside: +197.62%
Alpine Immune Sciences
Apr 11, 2024
Downgrades: Neutral
Price Target: n/a
Current: $64.56
Upside: -
Geron
Apr 10, 2024
Reiterates: Outperform
Price Target: $6
Current: $3.79
Upside: +58.31%
Foghorn Therapeutics
Apr 10, 2024
Reiterates: Outperform
Price Target: $13
Current: $5.49
Upside: +136.79%
Black Diamond Therapeutics
Apr 8, 2024
Maintains: Outperform
Price Target: $10 → $16
Current: $5.89
Upside: +171.65%
Aprea Therapeutics
Mar 27, 2024
Maintains: Outperform
Price Target: $9 → $11
Current: $5.20
Upside: +111.54%
Compass Therapeutics
Mar 22, 2024
Reiterates: Outperform
Price Target: $8
Current: $1.45
Upside: +451.72%
Tyra Biosciences
Mar 21, 2024
Reiterates: Outperform
Price Target: $28
Current: $15.67
Upside: +78.69%
CytomX Therapeutics
Mar 12, 2024
Reiterates: Neutral
Price Target: $3
Current: $1.59
Upside: +88.68%
IGM Biosciences
Mar 8, 2024
Reiterates: Outperform
Price Target: $20
Current: $9.40
Upside: +112.77%
Elevation Oncology
Mar 7, 2024
Maintains: Outperform
Price Target: $5 → $8
Current: $3.62
Upside: +120.99%
Kura Oncology
Feb 28, 2024
Reiterates: Outperform
Price Target: $37
Current: $19.65
Upside: +88.30%
Zentalis Pharmaceuticals
Feb 28, 2024
Maintains: Neutral
Price Target: $12 → $15
Current: $11.06
Upside: +35.62%
Arvinas
Feb 28, 2024
Maintains: Outperform
Price Target: $33 → $59
Current: $32.37
Upside: +82.27%
Arcus Biosciences
Feb 22, 2024
Reiterates: Outperform
Price Target: $30
Current: $15.55
Upside: +92.93%
Cullinan Oncology
Feb 15, 2024
Initiates: Outperform
Price Target: $30
Current: $25.30
Upside: +18.58%
Monte Rosa Therapeutics
Feb 15, 2024
Initiates: Outperform
Price Target: $11
Current: $5.33
Upside: +106.38%
Omega Therapeutics
Jan 4, 2024
Reiterates: Outperform
Price Target: $12
Current: $2.27
Upside: +428.63%
IDEAYA Biosciences
Nov 13, 2023
Reiterates: Outperform
Price Target: $43
Current: $39.94
Upside: +7.66%
Replimune Group
Nov 8, 2023
Reiterates: Outperform
Price Target: $52
Current: $6.42
Upside: +709.97%
Janux Therapeutics
Nov 8, 2023
Reiterates: Outperform
Price Target: $24
Current: $47.39
Upside: -49.36%
Day One Biopharmaceuticals
Nov 7, 2023
Maintains: Outperform
Price Target: $39 → $35
Current: $14.92
Upside: +134.58%
Werewolf Therapeutics
Aug 24, 2023
Initiates: Outperform
Price Target: $9
Current: $6.75
Upside: +33.33%
Atreca
Aug 14, 2023
Downgrades: Neutral
Price Target: $4 → $1
Current: $0.08
Upside: +1,112.12%
Tango Therapeutics
May 10, 2023
Reiterates: Outperform
Price Target: $18
Current: $7.44
Upside: +141.94%
Arbutus Biopharma
May 19, 2020
Upgrades: Outperform
Price Target: n/a
Current: $2.73
Upside: -